All In Biotech

Drug Trial Radar · NCT04093570

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Last checked: Nov 20, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

332

Planned (sponsor's estimate)

Start

Sep 30, 2019

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Taiho Oncology, Inc.Industry
Sponsor type
Industry
First posted
Sep 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Extension study to provide ongoing long-term treatment with ASTX727 for participants who were benefitting from ASTX727 treatment in a previous Taiho (formerly Astex)-sponsored clinical study of ASTX727 (including, but not limited to ASTX727-01 \[NCT02103478\], ASTX727-02 \[NCT03306264\], ASTX727-04 \[NCT03813186\]), ASTX727-06 \[NCT04093570\] food effect substudy, ASTX727-17 \[NCT04953897\], and ASTX727-18 \[NCT04953910\] to obtain long-term safety information. The purpose of the Food Effect Substudy was to evaluate the pharmacokinetics (PK) and safety of decitabine and cedazuridine when ASTX727 was given under fed (high-calorie/high-fat meal or low-calorie/low-fat meal) versus fasted conditions. Food Effect Substudy has now completed.

Conditions

  • Acute Myeloid Leukemia
  • Chronic Myelomonocytic Leukemia
  • Myelodysplastic Syndromes

Interventions

  • ASTX727Drug

    ASTX727 film-coated, immediate-release FDC tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Main Extension Study: Safety: Number of Participants with Treatment-Emergent Adverse Events (TEAEs)Time frame: From date of transition into this extension study until 30 days following the last dose, up to approximately 2 years
  2. Food Effect Substudy: AUC0-last: Area Under the Plasma Concentration-time Curve From Time Zero to Last Concentration Measured of Decitabine in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 ( up to 28 days)
  3. Food Effect Substudy: AUC0-last: Area Under the Plasma Concentration-time Curve From Time Zero to Last Concentration Measured of Cedazuridine in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)
  4. Food Effect Substudy: AUC0-last: Area Under the Plasma Concentration-time Curve From Time Zero to Last Concentration Measured of Cedazuridine-epimer in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)
  5. Food Effect Substudy: AUC0-8h: Area Under the Concentration-time Curve From Time Zero to 8 Hours of Decitabine in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)
  6. Food Effect Substudy: AUC0-8h: Area Under the Concentration-time Curve From Time Zero to 8 Hours of Cedazuridine in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)
  7. Food Effect Substudy: AUC0-8h: Area Under the Concentration-time Curve From Time Zero to 8 Hours of Cedazuridine-epimer in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)
  8. Food Effect Substudy: AUC0-24h: Area Under the Concentration-time Curve From Time Zero to 24 Hours of Decitabine in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)
  9. Food Effect Substudy: AUC0-24h: Area Under the Concentration-time Curve From Time Zero to 24 Hours of Cedazuridine in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)
  10. Food Effect Substudy: AUC0-24h: Area Under the Concentration-time Curve From Time Zero to 24 Hours of Cedazuridine-epimer in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)
  11. Food Effect Substudy: AUC 0-inf: Area Under the Concentration-time Curve From Time Zero to Infinity of Decitabine in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)
  12. Food Effect Substudy: AUC 0-inf: Area Under the Concentration-time Curve From Time Zero to Infinity of Cedazuridine in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)
  13. Food Effect Substudy: AUC 0-inf: Area Under the Concentration-time Curve From Time Zero to Infinity of Cedazuridine-epimer in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)
  14. Food Effect Substudy: Cmax: Maximum Observed Plasma Concentration of Decitabine in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)
  15. Food Effect Substudy: Cmax: Maximum Observed Plasma Concentration of Cedazuridine in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)
  16. Food Effect Substudy: Cmax: Maximum Observed Plasma Concentration of Cedazuridine-epimer in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)
  17. Food Effect Substudy: Tmax: Time of First Occurrence of Cmax of Decitabine in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)
  18. Food Effect Substudy: Tmax: Time of First Occurrence of Cmax of Cedazuridine in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)
  19. Food Effect Substudy: Tmax: Time of First Occurrence of Cmax of Cedazuridine-epimer in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)
  20. Food Effect Substudy: T1/2: Terminal Half Life of Decitabine in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)
  21. Food Effect Substudy: T1/2: Terminal Half Life of Cedazuridine in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)
  22. Food Effect Substudy: T1/2: Terminal Half Life of Cedazuridine-epimer in the Fasted and Fed StateTime frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24 hours post dose on Days 2 (fasted state) and 4 (fed state) in Cycle 1 (up to 28 days)

Locations

47 sites in 13 countries. Site status is shown where the registry gives one.

  • Compassionate Care Research Group

    Fountain Valley, California

  • Boca Raton Clinical Research

    Plantation, Florida

  • The University of Chicago Medical Center

    Chicago, Illinois

  • The Sidney Kimmel Comprehensive Cancer Center at John Hopkins

    Baltimore, Maryland

  • Cancer and Hematology Centers for Western Michigan

    Grand Rapids, Michigan

  • Mayo - Rochester

    Rochester, Minnesota

  • Hackensack Medical Center - 06 FE Study

    Hackensack, New Jersey

  • Hackensack Medical Center

    Hackensack, New Jersey

  • Rosewell Park Cancer Institute

    Buffalo, New York

  • Roswell Park Cancer Institute - 06 FE Study

    Buffalo, New York

  • Gabrail Cancer Center Research - 06 FE Study

    Canton, Ohio

  • Gabrail Cancer Center Research

    Canton, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Charleston Hematology Oncology Associates

    Charleston, South Carolina

  • Vanderbilt - Ingram Cancer Center

    Nashville, Tennessee

  • Baylor Scott White University Medical Center

    Dallas, Texas

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • May Cancer Center

    San Antonio, Texas

  • Kadlec Clinic Hematology and Oncology

    Kennewick, Washington

  • Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • Erebuni Medical Center

    Yerevan, Armenia

  • Hematology Center After Prof. R. Yeolyan (Adult Blood Disorders)

    Yerevan, Armenia

  • Hematology Center After Prof. R. Yeolyan (Clinic of Adults Oncology)

    Yerevan, Armenia

  • National Center of Oncology Named After V.A. Fanarjyan

    Yerevan, Armenia

  • Wiener Gesundheitsverbund - Klinik Hietzing 06 FE Study

    Vienna, Austria

  • Wiener Gesundheitsverbund - Klinik Hietzing 06 Study

    Vienna, Austria

  • Specialized Hospital for Active Treatment of Hematological Disease EAD

    Sofia, Bulgaria

  • University of Alberta Hospital

    Edmonton, Canada

  • QEII Health Sciences Centre

    Nova Scotia, Canada

  • The Ottawa Hosptial

    Ottawa, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Canada

  • Princess Margaret Cancer Center

    Toronto, Canada

  • Hôpital Emile Muller

    Mulhouse, Grand Est, France

  • Städtisches Klinikum Braunschweig

    Braunschweig, Lower Saxony, Germany

  • Universitätsklinikum Schleswig-Holstein - Campus Lübeck

    Lübeck, Schleswig-Holstein, Germany

  • Debreceni Egyetem Klinikai Kozpont, Belgyogyszati Klinika, B epulet, Hematologia

    Debrecen, Hungary

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Centrum Badań Klinicznych Piotr Napora Lekarze Sp. p.

    Wroclaw, Lower Silesian Voivodeship, Poland

  • Institutul Oncologic Bucuresti - Prof. Dr. Alexandru Trestioreanu

    Bucharest, Romania

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.